Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:YMTX

Yumanity Therapeutics (YMTX) Stock Price, News & Analysis

Yumanity Therapeutics logo

About Yumanity Therapeutics Stock (NASDAQ:YMTX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.56
$1.89
52-Week Range
N/A
Volume
6,790 shs
Average Volume
473,083 shs
Market Capitalization
$7.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Receive YMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMTX Stock News Headlines

JSPR Jasper Therapeutics, Inc.
Cara Therapeutics Inc CARA
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Yumanity Therapeutics Inc.
See More Headlines

YMTX Stock Analysis - Frequently Asked Questions

Yumanity Therapeutics, Inc. (NASDAQ:YMTX) released its quarterly earnings data on Thursday, August, 12th. The company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by $0.19. The business earned $2.11 million during the quarter, compared to analysts' expectations of $2.27 million. Yumanity Therapeutics had a negative net margin of 660.61% and a negative trailing twelve-month return on equity of 263.34%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Yumanity Therapeutics investors own include NIO (NIO), Arch Therapeutics (ARTH), Aytu BioPharma (AYTU), Clarus Therapeutics (CRXTQ), Ford Motor (F), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
8/12/2021
Today
6/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:YMTX
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.50 million
Net Margins
-660.61%
Pretax Margin
-660.61%

Debt

Sales & Book Value

Annual Sales
$4.84 million
Price / Cash Flow
N/A
Book Value
$2.28 per share
Price / Book
N/A

Miscellaneous

Free Float
9,504,000
Market Cap
$7.46 million
Optionable
Not Optionable
Beta
0.32
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:YMTX) was last updated on 6/23/2025 by MarketBeat.com Staff
From Our Partners